Artery disease
Conditions
Interventions
Experimental:Rivaroxaban 10 mg once daily for a period of 7 days.
Control group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-80 years old; 2. Successful coronary angiography +/- interventional therapy through the right radial artery approach; 3. Radial artery B-ultrasonography indicated radial artery occlusion; 4. The patient was informed of the project content and agreed to be included in the study.
Exclusion criteria
Exclusion criteria: 1. Other complications associated with radial artery puncture (including forearm hematoma, pseudoaneurysm, etc.) ; 2. Current anticoagulation for other indication; 3. Patients with high blood risk (any of the following conditions: CRUSADE score is high risk; History of gastrointestinal bleeding within 1 month; Previous history of hemorrhagic stroke or ischemic stroke within 3 months; Hemoglobin <100 g/L or platelet count <50 x 10^9/L) ; 4. Hemo-dynamic instability; 5. Patients with renal insufficiency (eGFR<30mL/min); 6. Patients with hepatic insufficiency (Child-Pugh grade B or C) ; 7. Patients with allergic reaction to rivaroxaban.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Right radial artery occlusion; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms of Radial Artery Occlusion; | — |
Countries
China
Contacts
Public ContactShan Peiren
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed